Concepedia

Author

Qin Ryan

National Cancer Institute

Also Known As

Qin C. Ryan, Qin Ryan

14

Publications

1.2K

Citations

10

H-Index

31

Concepts

All Affiliations

National Cancer InstituteCenter for Cancer ResearchCenter for Drug Evaluation and ResearchUnited States Food and Drug AdministrationCenters for Medicare and Medicaid Services
QR

About

Qin Ryan is an author at National Cancer Institute specializing in medicine, radiation oncology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

80

2

Health Sciences

2

2

36

3

Pharmacology

2

2

44

4

Immunology

1

1

24

5

Pathology

1

1

19

Qin Ryan

×

9

Publications

1.2K

Citations

9

H-Index

YearCitations

Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

Qin Ryan, Donna Headlee, Milin Acharya,

Journal of Clinical Oncology

2005

406

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2

Qin Ryan, Amna Ibrahim, Martin H. Cohen,

The Oncologist

2008

303

Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products

Cunlin Wang, David J. Graham, Robert C. Kane,

JAMA

2015

210

Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies

Shivaani Kummar, Martin Gutierrez, Erin R. Gardner,

Clinical Cancer Research

2007

130

Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare

Cunlin Wang, Robert C. Kane, Mark Levenson,

JAMA Internal Medicine

2016

39

Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry.

Eun Joo Chung, Sunmin Lee, Edward A. Sausville,

PubMed

2005

24

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer

Milin Acharya, Judith E. Karp, Edward A. Sausville,

Investigational New Drugs

2006

20

Fluorodeoxyglucose Positron Emission Tomography in the Presence of Cardiac Metastases

John D. Nguyen, Jorge A. Carrasquillo, Richard F. Little,

Clinical Nuclear Medicine

2003

19

A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms

William D. Figg, Manish Monga, Donna Headlee,

Cancer Chemotherapy and Pharmacology

2014

17

Page 1